STOCK TITAN

Perspective Therapeutics: Commodore reports 5.5% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. (CATX) is the issuer named in an amended ownership report by Commodore Capital LP, Commodore Capital Master LP, and the firm’s managing partners, Robert Egen Atkinson and Michael Kramarz. Each reporting person reports shared beneficial ownership of 6,598,046 common shares, equal to 5.5% of the class. The reported position consists entirely of shares they may acquire by exercising a pre-funded warrant, subject to a 9.99% Beneficial Ownership Limitation.

Beneficially owned shares 6,598,046 shares Shared beneficial ownership reported by each reporting person as of September 30, 2026; all are acquirable through a pre-funded warrant.
Percent of class 5.5% Reported for each reporting person.
Shares issued and outstanding 114,160,769 shares Reported as of September 30, 2026; used in the stated ownership-percentage calculation alongside warrant shares.
Beneficial Ownership Limitation 9.99% Limit applicable to exercise of the pre-funded warrant.
pre-funded warrant technical
"right to acquire through the exercise of a pre-funded warrant"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
Beneficial Ownership Limitation regulatory
"subject to a beneficial ownership limitation of 9.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CATX shares does Commodore Capital report beneficially owning?

Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson and Michael Kramarz each report shared beneficial ownership of 6,598,046 common shares, or 5.5% of the class. The reported shares are acquirable through a pre-funded warrant.

What ownership limit applies to the CATX pre-funded warrant?

The pre-funded warrant is subject to a 9.99% Beneficial Ownership Limitation. The reported beneficially owned position consists entirely of shares the reporting persons may acquire by exercising the warrant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





46489V302

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Commodore Capital LP
Signature:Michael Kramarz
Name/Title:Managing Partner
Date:11/16/2026
Commodore Capital Master LP
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:11/16/2026
Robert Egen Atkinson
Signature:Robert Egen Atkinson
Name/Title:Authorized Signatory
Date:11/16/2026
Michael Kramarz
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:11/16/2026
Exhibit Information

Exhibit 1: Joint Filing Agreement

Keep reading